V
Vivace Therapeutics
A venture-backed, oncology-focused portfolio-based drug discovery and development company
About Vivace Therapeutics
Vivace Therapeutics is a small molecule drug discovery and development company with a focus on oncology. The company is centered on creating new treatments for cancer patients by targeting specific biological pathways. Its main focus is on the Hippo-YAP pathway, which is a key regulator of cell growth and is often dysregulated in cancer.
Vivace Therapeutics' business model is based on a portfolio-based approach to drug discovery and development. This means that the company is developing multiple drug candidates at the same time, which helps to diversify risk and increase the chances of success. The company's primary customers are patients with advanced cancers, such as mesothelioma, who have limited treatment options. Vivace Therapeutics operates in the highly competitive oncology market, which is characterized by rapid innovation and a constant need for new and effective treatments.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Mar 2025 | $35M | $140M | Cenova Capital · Canaan · RA Capital Management | ↗ |
| SERIES COther financing | Dec 2020 | $30M | $120M | Boxer Capital · Canaan · RA Capital Management · Tavistock Group | — |
Growth signals
Latest recorded traffic for Vivace Therapeutics is 1.9K monthly website visits, down 9.5% over the last three months. Vivace Therapeutics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vivace Therapeutics in the San Mateo ecosystem
The Vivace Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Series B and later3 investors entered at this stage
Tavistock Group
Boxer Capital
RA Capital Management
Other known investors2 additional known investors
University of California, San Diego
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vivace Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vivace Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.















